THE Federal Government has announced the funding on the Pharmaceutical Benefits Scheme (PBS) of the first treatment for the autoimmune disease active non-radiographic axial spondyloarthritis.
Simponi (golimumab) from Janssen counters inflammation from the debilitating spinal arthritis which affects more than 30,000 Australians aged in their 20s or 30s.
The once-a-month treatment blocks a specific protein responsible for painful inflammation triggered by the body's immune system and will be listed from 01 Dec for patients who have had an inadequate response or are intolerant to NSAIDs.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Oct 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Oct 18
